Streicher, Howard
National Institutes of Health · National Cancer Institute
4 papers on CoChatORCID 0000-0003-3683-9804
Most cited papers
- Verified
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology
Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Cited by 759
- Verified
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., Delbrook, C., Lodish, M., Bishop, R., Wolchok, J. D., et al. (2016) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 331
- Verified
Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609
Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., et al. (2020) · Journal of Clinical Oncology
Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers
Cited by 184
- Verified
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses
Seligson, N. D., Chen, J. L., Goodrich, A. C., Van Tine, B. A., Campbell, J. D., Richards, A. L., Antonescu, C. R., Liebner, D. A., Milhem, M. M., Streicher, H., et al. (2024) · Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment
Cited by 21
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free